Home
Company
Product
Regulation
China
Data
Exhibition
Interview
中文版
Home
Company
Product
Regulation
China
Data
Exhibition
Interview
中文版
Search

Bloody Bar 30K Triple Twist E-cigarette Launched in UK with 3 * "2+10" Design

Jan.07.2025
Bloody Bar 30K Triple Twist E-cigarette Launched in UK with 3 * "2+10" Design
UK introduces new Bloody Bar 30K Triple Twist e-cigarette with unique pod design and multiple flavor options.

Special announcement:

This article is for internal industry communication only and does not make any recommendations for brands or products.

The images presented in this article are for descriptive purposes only and are not intended as advertisements for any products.

This article is prohibited for minors to access.

 

UK e-cigarette market have launched a new e-cigarette - the Bloody Bar 30K Triple Twist. This product features a unique design that combines 3 "2+10" combinations, offering triple flavors and 30,000 puffs.

 

Bloody Bar 30K Triple Twist E-cigarette Launched in UK with 3 *
Translation: Bloody Bar 30K Triple Twist｜Image source: goldenvape

 

 

Specifically, the product specifications of the Bloody Bar 30K Triple Twist are as shown in the table below.

Bloody Bar 30K Triple Twist E-cigarette Launched in UK with 3 *
Bloody Bar 30K Triple Twist Parameters | Design: 2Firsts

The key feature of the Bloody Bar 30K Triple Twist is its unique pod design. This e-cigarette device comes with three "2+10" pods, each with a total e-liquid capacity of 36 milliliters. Additionally, each pod can be filled with a different e-liquid flavor, allowing for quick flavor changes through a rotating mechanism.

 

Previously, Bloody Bar released a 2-in-1 e-cigarette called the Bloody Bar Ultra Twist 20K, which is capable of providing two different flavors at the same time. Users can easily switch between flavors by rotating the mouthpiece.

 

Bloody Bar 30K Triple Twist E-cigarette Launched in UK with 3 *
Public Notice | Image Source: MHRA

 

It is worth noting that the UK's Medicines and Healthcare products Regulatory Agency (MHRA) e-cigarette notification system shows that "BLOODY BAR TRIPLE TWIST 30K" was publicly announced in November 2024. The applicant is BOWMAN SPECIALISED LIQUIDS LIMITED, founded by Christopher Bowman in 2012, a company focused on research and sales of e-cigarette e-liquids.

 

Bloody Bar 30K Triple Twist E-cigarette Launched in UK with 3 *
BOWMAN SPECIALISED LIQUIDS LIMITED Website | Image source: BOWMAN

 

Currently, the Bloody Bar 30K Triple Twist has been listed on various UK e-cigarette distributor websites such as vapesourcing, ecigone, and vapeuk, with a price of approximately £12.99. However, the product has not yet been made available for sale on the company's official website.

 

Bloody Bar 30K Triple Twist E-cigarette Launched in UK with 3 *
Blood Bar 30K Triple Twist | Image source: vapesourcing

 

2Firsts will continue to monitor the performance and market trends of e-cigarette products globally, providing accurate and authoritative industry information to the public.

 

2FIRSTS, a product column, is dedicated to providing readers with the latest information on new products in the tobacco industry. To gather and share first-hand industry information more widely, 2FIRSTS welcomes readers to submit articles and share the latest products in the e-cigarette field with us.

 

If you have any unique insights or information, please feel free to contact us anytime via email at info@2firsts.com.

 

References:
[1] Bloody Bar 30K Triple Twist
Also Read:
[1] ALD Officially Reveals IC20K Adjustable Ice E-Cigarette
[2] RELX Launches Maxgo Pro 22000 in the UK with a 2+10+10 Design
[3] LOST VAPE Launches 50,000-Puff Ice & Nic Adjustable Orion Bar with 360° 3D Curved Screen
[4] Geek Bar Pulse Mintz: New Mint Flavor E-cigarette Launched in US
[5] Sikary VFLY SUPER DTL: The World's First Pod-System E-Hookah?
[6] OXBAR GTURBO Launches in Canada with 5 Adjustable Nicotine Levels
#Europe#Open system e-cigarettes#UK#Products

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

China Tobacco Regulation Shift：Policy Updates and Market Impact
China Tobacco Regulation Shift：Policy Updates and Market Impact
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
JAMA Study: U.S. Vape Directories Fail to Sustainably Curb Unlisted Sales as Product Shifts May Redistribute Brand Share 2Firsts Recommended
JAMA Study: U.S. Vape Directories Fail to Sustainably Curb Unlisted Sales as Product Shifts May Redistribute Brand Share 2Firsts Recommended
A study by CDC Foundation researchers found no sustained decline in e-cigarette sales across Alabama, Oklahoma and Louisiana, the first three U.S. states to implement e-cigarette directory laws. Louisiana initially saw a significant sales decline, followed by a rebound and a persistent reduction in product availability. Sales also shifted from nontobacco-flavored disposables toward prefilled cartridges, with Vuse Alto driving much of the increase in menthol cartridges. By April 2025, unlisted products still accounted for more than half of e-cigarette nicotine sales in all three states.
Sep.18
Special Report | Altria's NACS Booth Raises Questions Over U.S. Tobacco Advertising Warnings
Special Report | Altria's NACS Booth Raises Questions Over U.S. Tobacco Advertising Warnings
During its coverage of Altria's booth at NACS Show 2026, 2Firsts documented product displays that prompted questions about U.S. tobacco advertising warning requirements. Following public comments from a former FDA official, 2Firsts sought responses from Altria and independently consulted U.S. regulatory lawyer Azim Chowdhury. Altria maintained that its B2B communications complied with applicable laws, while Chowdhury explained that federal warning rules provide no general trade-show exemption for e-cigarettes and nicotine pouches. The special report examines the broader regulatory implications.
Nov.04
Athletes Back Skoka's $21.5 Million Nicotine Pouch Venture: Can Its Consumer Health Founder Make an FDA-Focused Strategy Pay Off?
Athletes Back Skoka's $21.5 Million Nicotine Pouch Venture: Can Its Consumer Health Founder Make an FDA-Focused Strategy Pay Off?
U.S. nicotine pouch startup Skoka Inc. has raised $21.5 million and committed $15 million to an FDA regulatory and scientific research program. Founder Dan Aziz previously built dietary supplement brand Premama, which was acquired by Dr. Reddy's Laboratories in 2023. Skoka is combining proprietary formulations, ingredient transparency and equity investment from professional athletes. The company submitted a bundled PMTA covering 55 products on October 1, 2026. Aziz said Skoka declined an opportunity to enter retail in 2025, prioritizing product research and regulatory submissions instead. It now targets a U.S. retail launch in 2027, subject to FDA requirements. Its products have not received marketing authorization.
Business
Nov.04
FRE and ALP Push Modern Oral to 48% of Q2 Sales as Turning Point Brands Changes CEO and Lowers Profit-Guidance Ceiling
FRE and ALP Push Modern Oral to 48% of Q2 Sales as Turning Point Brands Changes CEO and Lowers Profit-Guidance Ceiling
Turning Point Brands said Executive Chairman David E. Glazek will become CEO on October 1, replacing Graham Purdy, who is stepping down for personal reasons. The company narrowed its 2026 adjusted EBITDA outlook to $70 million-$80 million from $70 million-$90 million while maintaining Modern Oral gross sales guidance of $330 million-$350 million and net sales guidance of $260 million-$270 million. In the second quarter, Modern Oral net sales rose 128% to $68.4 million and accounted for 48% of company-wide net sales. Adjusted EBITDA fell 50% year over year. TPB shares closed about 10% lower on September 21.
Market
Sep.22 by 2Firsts Perspectives
Ukraine Raises Excise Stamp Fees for Tobacco, Heated Tobacco and Vape Liquids by 30.5% as Parliament Backs E-Excise Delay to 2027
Ukraine Raises Excise Stamp Fees for Tobacco, Heated Tobacco and Vape Liquids by 30.5% as Parliament Backs E-Excise Delay to 2027
Ukraine's Cabinet of Ministers adopted Resolution No. 1259 on October 15, 2026, increasing excise stamp production fees for tobacco products and e-cigarette liquids by approximately 30.5%, from UAH 0.1643 to UAH 0.2144 per stamp. Fees for alcoholic beverages rose by about 30.2%. Separately, Ukraine's parliament passed Bill No. 15532 on October 13, proposing to postpone the full implementation of electronic excise stamps and traceability for alcohol, tobacco and e-cigarette liquids from November 1, 2026, to July 1, 2027. Parliament cited additional testing, configuration and integration requirements. The bill was sent to the president for signature on October 19.
Regulations
Oct.21
Related Topics
HEADLINE News Product
Related Read
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
JAMA Study: U.S. Vape Directories Fail to Sustainably Curb Unlisted Sales as Product Shifts May Redistribute Brand Share 2Firsts Recommended
JAMA Study: U.S. Vape Directories Fail to Sustainably Curb Unlisted Sales as Product Shifts May Redistribute Brand Share 2Firsts Recommended
Special Report | Altria's NACS Booth Raises Questions Over U.S. Tobacco Advertising Warnings
Special Report | Altria's NACS Booth Raises Questions Over U.S. Tobacco Advertising Warnings
Athletes Back Skoka's $21.5 Million Nicotine Pouch Venture: Can Its Consumer Health Founder Make an FDA-Focused Strategy Pay Off?
Athletes Back Skoka's $21.5 Million Nicotine Pouch Venture: Can Its Consumer Health Founder Make an FDA-Focused Strategy Pay Off?
FRE and ALP Push Modern Oral to 48% of Q2 Sales as Turning Point Brands Changes CEO and Lowers Profit-Guidance Ceiling
FRE and ALP Push Modern Oral to 48% of Q2 Sales as Turning Point Brands Changes CEO and Lowers Profit-Guidance Ceiling
2Firsts Perspectives
Ukraine Raises Excise Stamp Fees for Tobacco, Heated Tobacco and Vape Liquids by 30.5% as Parliament Backs E-Excise Delay to 2027
Ukraine Raises Excise Stamp Fees for Tobacco, Heated Tobacco and Vape Liquids by 30.5% as Parliament Backs E-Excise Delay to 2027
FOLLOW US ON SOCIAL MEDIA
Contact: info@2firsts.com
Stay up to date.
Submit your email to receive weekly newsletter on the most relevant news of the e-cigarette industry.
© 2026 2FIRSTS. All Right Reserved.
2FIRSTS is only accessible to industry practitioners, researchers, media and other professionals. Access by minors is prohibited.
This website provides services to users outside the Chinese mainland.
English
English
中文